New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.

Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...

The U.S. Food and Drug Administration has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and ...

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment ...

Please provide your email address to receive an email when new articles are posted on . Daily aspirin use after adjuvant therapy did not improve outcomes for patients with colorectal cancer. Daily ...

An interview with Dr. Jennifer Griggs from University of Michigan on Adjuvant Endocrine Therapy for Women with Hormone Receptor Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.

Adjuvant chemoradiation combined with immunotherapy for patients with high-risk resectable extrahepatic cholangiocarcinoma and gallbladder cancer: A phase II, multicenter, randomized controlled trial ...

The guidelines provide a starting place for conducting studies and collecting data to confirm what experts currently are recommending in the absence of adequate data.

ATHENS, Greece — Real-world data confirm that complete nodal dissection following a positive sentinel lymph node biopsy in patients with stage III melanoma and micrometastases does not significantly ...